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ABSTRACT
Enzymes of intermediary metabolism are often re-
ported to have moonlighting functions as RNA-
binding proteins and have regulatory roles be-
yond their primary activities. Human serine hydrox-
ymethyltransferase (SHMT) is essential for the one-
carbon metabolism, which sustains growth and pro-
liferation in normal and tumour cells. Here, we char-
acterize the RNA-binding function of cytosolic SHMT
(SHMT1) in vitro and using cancer cell models. We
show that SHMT1 controls the expression of its
mitochondrial counterpart (SHMT2) by binding to
the 5′untranslated region of the SHMT2 transcript
(UTR2). Importantly, binding to RNA is modulated by
metabolites in vitro and the formation of the SHMT1–
UTR2 complex inhibits the serine cleavage activity
of the SHMT1, without affecting the reverse reaction.
Transfection of UTR2 in cancer cells controls SHMT1
activity and reduces cell viability. We propose a novel
mechanism of SHMT regulation, which interconnects
RNA and metabolites levels to control the cross-talk
between cytosolic and mitochondrial compartments
of serine metabolism.
INTRODUCTION
Many eukaryotic enzymes belonging to the intermediary
metabolism have been shown to perform other functions in
addition to their primary metabolic role (so-called moon-
lighting proteins). A large number of these metabolic en-
zymes are able to function as RNA-binding proteins and
play crucial roles in post-transcriptional gene regulation
and in the control of activity and localization of enzymatic
complexes (1). Examples of such moonlighting enzymes in-
clude thymidylate synthase (TYMS), dihydrofolate reduc-
tase (DHFR) and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) (2–4).
Human serine hydroxymethyltransferase (SHMT) catal-
yses the reversible conversion of serine and tetrahydrofo-
late (THF) into glycine and 5,10-methylenetetrahydrofolate
(CH2-THF). This reaction is central in the serine-glycine
one-carbon metabolism (1C-metabolism), a complex net-
work fuelling the biosynthesis of nucleotide precursors,
NADPH and methylation factors and thus sustaining cell
growth and proliferation. The human genome contains two
shmt genes, encoding three main SHMT isoforms that dif-
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fer in sequence and/or localization: one mitochondrial iso-
form, named SHMT2, and two cytosolic isoforms, SHMT1
and SHMT2, the latter lacking the mitochondrial import
signal present in SHMT2 and thus localizing in the cytosol.
The mitochondrial SHMT2 isozyme is mainly involved
in the serine-derived production of both glycine and one-
carbon units necessary to fuel the synthesis of purines,mito-
chondrial thymidine monophosphate (dTMP) and antioxi-
dant molecules such as NADPH and glutathione. SHMT2
is also required for the maintenance of transfer RNA
(tRNA) pools inside the mitochondria, affecting the levels
of formylmethionyl-tRNA and other methylated tRNAs,
and thereby controlling the translation of mitochondrial
respiratory complexes (5–8). By contrast, SHMT1 is likely
to have a more versatile metabolic role, since it can switch
the directionality of the reaction depending on cell type
and metabolic needs (5,9). In addition, SHMT1, together
with SHMT2, undergoes nuclear localization during the
S-phase of the cell cycle to participate in the synthesis of
dTMP (10,11).
The reaction catalyzed by SHMT is pivotal for the
metabolic reprogramming of cancer cells and, not surpris-
ingly, tumours often overexpress one or more isoforms (12).
SHMT1 and SHMT2 are up-regulated in patient-derived
lung cancer tissue samples (13,14). We previously showed
that SHMT1 knockdown in A549 and H1299 lung cancer
cell lines triggered apoptosis and induced a compensatory
increase of SHMT2 expression by a yet unknown mecha-
nism, suggesting that SHMT1 might be involved in the reg-
ulation of the other isoforms (13). Since the SHMT1 can
bind RNA (15), we have hypothesized that the reported reg-
ulation could occur at the post-transcriptional level. There
are many examples of regulatory proteins and enzymes in-
teracting with the 5′untranslated regions (5′UTRs) of their
target transcripts to modulate the stability and the transla-
tion of messenger RNAs (mRNAs) (16), including TYMS
and DHFR (2,3,17).
We therefore investigated whether SHMT1 could regu-
late the expression of the other isozymes by binding to their
transcripts via 5′UTR recognition. Here, we characterized
the binding of SHMT1 to the 5′UTR of its mRNA and
to three 5′UTRs of SHMT2 isoforms differently expressed
in lung cancer, chosen on the basis of their relative abun-
dance in RNA-sequencing data (18). Our data demonstrate
that SHMT1 binds specifically and with high affinity to the
5′UTR of SHMT2, affecting the expression and the trans-
lation of the corresponding transcript. The SHMT1/RNA
interaction is modulated by the enzyme’s substrates. Unex-
pectedly, binding of SHMT1 to the RNAmoiety selectively
inhibits the SHMT1 enzymatic activity, since the cleavage
of serine to glycine is significantly more affected than the
opposite reaction (i.e. glycine to serine). Our results show
that the RNA-mediated inhibition is also effective in can-
cer cell lines, suggesting that it may contribute to control
serine consumption by the cytosolic SHMT1.
In summary, our work allow us to assign a biologically
relevant role to the moonlighting RNA-binding activity of
SHMT1 (19) and to propose a novel regulatory mechanism
involving SHMT1,RNA species andmetabolites important
to fine-tune the interplay between cytosolic and mitochon-
drial isozymes.
MATERIALS AND METHODS
Materials
Chemicals and reagents 2-(4-chlorophenyl)ethylamine,
ethyl chloroformate (ECF), diethyl ether, ethyl acetate,
dichloromethane and thymidine 5′-monophosphate dis-
odium salt were obtained from Sigma-Aldrich. Tetrahydro-
folate and (6S)-5-formyl tetrahydrofolate were kindly
provided by Merck & Cie (Schaffhausen, Switzer-
land). Tritiated glycine used in the radioisotopic assay
([2−3H]glycine) was purchased from Perkin Elmer. (6R,S)-
5-Formyl-5,6,7,8-tetrahydropteroylpenta- -L-glutamic
acid lithium salt (5-CHO-THF-Glu5) was purchased from
Schircks Laboratories, Bauma, Switzerland. All other
reagents used in the enzymatic assays were obtained from
Sigma-Aldrich.
Protein expression and purification
Wild-type and mutant SHMT genes were cloned into a
pET22b(+) vector (Novagen) and expressed as N-terminal
Histidine-tagged fused proteins in Escherichia coli (BL21-
DE3). Purification was performed as described in Giar-
dina et al. (20). Briefly: cells were sonicated, and the sol-
uble proteins were purified by affinity chromatography on
a 5 ml HP-chelating column (GE Healthcare) loaded with
nickel ions. Protein was eluted with 0.3 M imidazole. Pro-
tein buffer was then exchanged on desalting columns PD10
(GE Healthcare) and the histidine tag removed by pro-
teolytic digestion with 1U/mg of thrombin (SIGMA) at
16◦C for 15 h. The digestion mix was then loaded again
on the HP-chelating column and thrombin eluted in the
flow thought, whereas SHMT, which binds with low affin-
ity, was eluted with 0.1 M imidazole. The proteins were
then concentrated and injected into a Superdex 200 col-
umn (either 10/300 or 16/60; GE Healthcare) and eluted
with the following buffer; 20 mM 4(-2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.4, 5% glyc-
erol, 100 mM NaCl (for SHMT1 and Y82A) or 200 mM
NaCl (for K157S-K158S), flash freezed in liquid nitro-
gen and stored at −20◦C. All proteins resulted mainly
tetrameric in solution; the K157S-K158S mutant required
the addition of 200 M pyridoxal phosphate (PLP) to
the running buffer to fully populate the tetrameric state,
whereas in the absence of PLP it eluted as a mixture of
tetramer (55%) and dimer (45%) (Supplementary Figure
S4A). The dichroic spectra of the two mutants superpose
with the wild-type enzyme and their thermal stability is
slightly reduced (Supplementary Figure S4B-C), as ob-
served for other mutations located near the active site or
the tetrameric interface (11).
In vitro transcription
pGL3 plasmids (pGL3 Control) containing the specific
UTRs cloned upstream of the luciferase gene were provided
by GeneArt/Invitrogen (Ratisbonne, Germany).
UTR sequences were amplified by polymerase chain re-
action (PCR) from pGL3 plasmids using primers designed
to include the T7 promoter sequence upstream of the UTR
PCR fragment (primers listed in Supplementary Table S1).
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PCR products were purified from agarose gel using the Nu-
cleospin Gel and PCR Clean-up Kit (Macherey-Nagel).
The DNA fragments generated by PCR were used as tem-
plates to produce the corresponding RNA sequences with
Ribomax Large Scale RNA Production System-T7 Kit
(Promega).
Biotinylation of RNA fragments
The UTR sequences were labelled at the 3′ end
with a molecule of cytidine-5′-phosphate-3′-(6-
aminohexyl)phosphate labelled with biotin (pCp-biotin)
using the Pierce™ RNA 3′ End Biotinylation Kit (Thermo
Scientific) and purified according to manufacturer instruc-
tions.
Electrophoretic mobility shift assay
Gel mobility shift assays were conducted by incubating a
fixed amount of RNA with fixed or increasing concentra-
tions of purified human SHMT1. For competition assays
increasing concentrations of unlabelled competitors UTRs
were added to the reaction mixture. To determine the effect
of metabolites upon RNA binding, the enzyme was pre-
incubated with an excess of serine or glycine and 5-CHO-
THF-Glun for 5 min at room temperature (RT), the latter
being a substrate analogue stable in an oxidative environ-
ment. Electrophoretic mobility shift assays (EMSA) on the
K157S/K158Smutant were run both in the absence (Figure
6D) and presence of PLP (data not shown), obtaining a sim-
ilar binding profile, thus excluding that the dimeric aggre-
gation state, partially populated in this mutant in absence
of PLP (Supplementary Figure S4A), could hamper RNA
binding.
All the components were incubated at RT for 30 min in
12 l of binding buffer (20 mM HEPES pH 7.4, 100 mM
NaCl) containing 20 g/ml bovine serum albumin (BSA),
1 g of tRNA, 1 U/l of recombinant Rnasin ribonucle-
ase Inhibitor and 8% (v/v) glycerol. The reaction mixtures
were separated onto 4% nondenaturing polyacrylamide gels
in 0.5× TBE buffer (45 mM Tris-Borate, 1 mM ethylenedi-
aminetetraacetic acid, pH 8.6). For the visualization of un-
labelled sequences, gels were stained with SYBR Safe (In-
vitrogen) in 30 ml of 0.5× TBE. To detect biotin-labelled
RNA, gels were transferred onto Immobilon-Ny+ posi-
tive charged nylon membranes (0.45 m) in 0.5× TBE, the
RNA was then cross-linked to the membrane using a hand-
held UV lamp equipped with 314 nm bulbs. The biotin moi-
ety was detected by chemiluminescence using the Chemi-
luminescent Nucleic Acid Detection Module (Thermo Sci-
entific). In both experiments, images were acquired using
Chemidoc MP Imaging System (Bio-Rad). All experiments
were run in triplicate. Densitometric measurements of the
bands corresponding to free RNA molecules were trans-
formed into percentages, the amount of bound RNA (%
bound) was then calculated by subtracting the percentage
of free RNA from the total, the result was plotted as a
function of protein concentration. The apparent dissocia-
tion constants (Kdapp) were estimated fitting the data with
Equation (1), in which Bmax corresponds to the maximum
binding (100%) and [P] corresponds to the concentration of
SHMT1 in the reaction mixture.
% Bound = Bmax [P]
Kd + [P] (1)
Site-directed mutagenesis
SHMT mutants were produced by site-directed mutagen-
esis using the QuikChange Lightning Site-Directed Muta-
genesis Kit (Agilent Technologies). The pET28b contain-
ing the wild-type SHMT1 was used as template DNA. Two
complementary oligonucleotides, synthesized by Metabion
(Steinkirchen, Germany), were used as primers for the mu-
tagenesis reactions (primers listed in Supplementary Table
S1). Escherichia coli Neb5 cells were transformed to am-
plify the mutated plasmid and mutagenesis was verified by
sequencing.
Cell lines
H1299 cancer cells were grown in RPMI-1640 medium
supplemented with 2 mM L-glutamine, 100 IU/ml
penicillin/streptomycin and 10% fetal bovine serum (FBS;
Biowest USA). HAP1 and HAP1shmt2KO cells were
obtained from Horizon Discovery Ltd., Cambridge, UK
and maintained in IMDM medium (Gibco) supplemented
with 100 IU/ml penicillin/streptomycin and 10% FBS
(Biowest USA). Minimal medium (MEM) formulation and
MEM supplementations have been previously reported
(21).
Cells transfection
H1299 and HAP1-SHMT2KO cells were transiently trans-
fected with interference RNA sequences from Qiagen as
previously reported (13) using JetPrime (Polyplus transfec-
tion). For the rescue experiments, at 24 h after the transfec-
tion, the medium was replaced with fresh medium with the
specified supplementation.
RNA extraction and real-time qRT-PCR analysis
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen) following the manufacturer instructions. Re-
verse transcription reactions were performed on 1 g of to-
talRNAwithSuperScript First-Strand Synthesis SystemKit
(Invitrogen). Each PCR tube contained 5l 2×KAPASybr
Fast universal premix, 2 × 0.4 l primer, 1 l complemen-
tary DNA (1:5 diluted) and 3.2 l water (final volume 10
l). Reactions were performed using Stratagene MX3000P
(Stratagene, La Jolla, CA, USA). The cycling protocol was:
95◦C for 2min, 40 cycles of 95◦C for 5 s, 60◦C for 25 s, before
fluorescence detection. A melting curve was determined us-
ing the standard instrument protocol. Amplification speci-
ficity was assessed by analysis of melting curves. Relative
fold change of the expression of individual genes was calcu-
lated using the 2−Ct. Each sample was analysed in trip-
licate. Primer sequences are shown in Supplementary Table
S1.
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Western blotting
Cells were lysed in 8M urea (Sigma-Aldrich) and pro-
tein concentration was determined using the Biorad Pro-
tein Assay (Bio-Rad, Munchen, Germany). Protein sam-
ples (40 g) were subjected to Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis, transferred onto nitro-
cellulose membranes and then saturated with 5% BSA in
Tris-buffered saline with 0.1% Tween 20. Membranes were
then incubated with the primary antibody for 18 h at 4◦C
and subsequently with horseradish peroxidase-conjugated
secondary antibody for 1 h at RT. Membranes were washed
with Tris-buffered saline in 0.1% Tween 20 and devel-
oped using the chemiluminescence system Chemidoc MP
Imaging System (Bio-Rad). The anti-SHMT2, --actin and
the anti-goat and -mouse antibody were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); the anti-SHMT1
antibody was from Cell Signaling Technology (Danvers,
Massachusetts, USA).
Luciferase assay
Luciferase activity was determined after transfecting the
pGL3 plasmids into the H1299 cells. Cells were co-
transfected with 0.5 g Renilla luciferase as control of
transfection together with 1 g of the pGL3, pGL3-UTR2
or pGL3-UTR1 plasmid plus iscr or the specific interfer-
ence RNA (iRNA) against shmt1. The expression of Fire-
fly and Renilla luciferases was analysed 48 h after transfec-
tion using the Dual-Luciferase® Reporter Assay System
(Promega) in a Victor3™ multilabel counter (Perkin Elmer,
Waltham,Massachusetts,USA). Firefly luciferasewas stan-
dardized to the value of Renilla.
Trypan blue exclusion assay
The growthmediumwas collected and the cells were washed
once with phosphate buffered saline (PBS) (also collected).
Adherent cells were removed by treatment with trypsin,
which in turn was blocked using complete medium. All the
collected cell fractions were centrifuged 5 min at 1000 × g
and the supernatant carefully discarded. The harvested cells
were then washed with PBS, centrifuged 5 min at 1000 × g
and the supernatant discarded. Following the addition of a
0.4% (w/v) trypan blue solution (Sigma-Aldrich) cells were
transferred to a Burker counting chamber (Hirschmann,
Germany) and visualized using an Axioskop 2 plus micro-
scope (Carl Zeiss Microscopy, Switzerland). Cells stained
with trypan blue dye were considered nonviable.
In vitro enzymatic activity assays
All assays were carried out at 30◦C in 20 mM KPi buffer
at pH 7.2, treated with diethyl pyrocarbonate (DEPC). The
SHMT activity was measured using 0.2 M enzyme with
L-serine and THF as substrates by means of a spectropho-
tometric coupled assay, in which the 5,10-CH2-THF pro-
duced by the reaction was oxidized by the NAD-dependent
E. coli 5,10-CH2-tetrahydrofolate dehydrogenase (22). The
possible inhibition of methylenetetrahydrofolate dehydro-
genase by RNA was checked in an experiment in which the
activity of the enzyme (1 M) with 50 M 5,10-CH2-THF
and 250 MNADP+ was measured in the presence and ab-
sence of tRNA and UTR2. No inhibition was observed un-
der these conditions.
Two assays were used to analyse the inverse reaction.
The first assay uses glycine and 5-CHO-THF as substrates
and is based on the spectrophotometric measurement of the
quinonoid intermediate that develops when both ligands
bind to SHMT, forming an enzyme–glycine–folate ternary
complex. The quinonoid intermediate, which yields an in-
tense absorption band with a maximum at 502 nm, derives
from deprotonation of glycine, but it accumulates to a mea-
surable extent only when a folate ligand is also bound to
SHMT and a ternary complex is formed (23). Therefore, the
absorbance at 502 nm is proportional to the fraction of en-
zyme present as the ternary complex. The second assay is a
coupled assay carried out in the presence of 5,10-CH2-THF
and glycine substrates. The L-serine product of this reaction
is oxidized by a NAD+-dependent serine dehydrogenase.
The inhibition curves were obtained keeping fixed con-
centration of substrates (10 mM glycine, 10 mM L-serine,
5 M 5-CHO-THF and 80 M THF, 90 M 5,10-CH2-
THF) while varying the RNA concentration. All obtained
inhibition curves were fitted to Equation (2), in which [I]
corresponds to the RNA concentration.
%Activity = 100
(
1 − [I]
[I] + IC50
)
(2)
The characterization of the tRNA inhibition mechanism
was carried out using serine andTHFas substrates. In a first
series of experiments, L-serine concentration was held con-
stant at 10 mM, while THF was varied between 10 and 488
M. The single saturation curves obtained varying THF
at various RNA concentrations were fitted to a modified
Michaelis–Menten equation that accounts for substrate in-
hibition (Equation 3).
vi = vmax [THF]
Km + [THF]
(
1 + [THF]K iTHF
) (3)
Moreover, all the saturation curves were globally fitted
to amodifiedMichaelis–Menten equation that accounts for
both substrate inhibition and hyperbolic competitive inhi-
bition (Equation 4).
vi = vmax [THF]
Km
(
1+ [tRNA]Ki
1+ [tRNA]
αKi
)
+ [THF]
(
1 + [THF]K iTHF
) (4)
In these equations, vi stands for initial velocity,Vmax is the
maximum velocity, Km is the Michaelis–Menten constant
for THF,KiTHFis the substrate inhibition constant,Ki is the
RNA inhibition constant and α is the factor by which Ki
changes when THF is bound to the enzyme.
In a second series of experiments, THF concentrationwas
held constant at 80 mM, while L-serine was varied between
0.156 and 10 mM. The saturation curves obtained were fit-
ted to a Michaelis–Menten equation.
All spectrophotometric measurements were performed
using a Hewlett-Packard 8453 diode-array spectropho-
tometer. Fitting of data to equations was carried out with
the PRISM software (GraphPad, La Jolla, CA, USA).
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SHMT activity assay in living cells
SHMTactivitymeasurements in living cells were performed
using a radioisotope assay based on the capability of SHMT
to catalyze the exchange of the pro-2S proton of glycinewith
solvent (24,25). At 24 h post-transfection, H1299 cells were
detached using trypsin and washed twice in 2 ml of PBS
buffer followed by centrifugation to eliminate the growth
medium. Aliquots (100 l) of cells suspension were incu-
bated with [2−3H]glycine (2 × 109 dpm mol−1) (23 M)
for 4 h at 37◦C. Subsequently, samples were centrifuged to
remove cells and reactions were stopped by the addition
of 3% (w/v) trichloroacetic acid to remove radiolabelled
glycine and measure radioactivity in the solvent. Control
reactions were performed to correct for background ex-
change (these samples did not contain cells). All measure-
ments were performed in duplicate and were normalized on
the basis of protein concentration.
Serine consumption assay
Sample extraction and derivatization. Serine was analysed
according to the method of Gao et al. (26) with slight
modifications. Cells transfected as indicated were cultured
in MEM originally supplemented as described before and
specifically with 400 M serine. After 48 h, cells were har-
vested and centrifuged to eliminate cellular debris. Then,
450 l cell culture mediumwas spiked with 20 l of 0.7 mM
2-(4-chlorophenyl)ethylamine as an internal standard. The
first step of derivatization was performed by adding 350 l
of ethanol/pyridine (6:1) and 50 l of ECF. The reaction
mixture was then vortexed for 30 s and ultrasonicated for
60 s to increase the speed of reaction at RT. The derivatiza-
tion products were extracted with 700 l of n-hexane for 60
s and centrifuged for 5 min at 3000 rpm. The organic layer
was removed and the aqueous phase was adjusted to pH
≥12 with 0.1 ml 7MNaOH. The second derivatization step
was performed by adding a further 50 l of ECF and 700l
of n-hexane. The reaction mixture was again vortexed and
ultrasonicated as before, and then centrifuged at 3000 rpm
for 10 min. The organic layers were combined, dried un-
der N2, resuspended in dichloromethane and analysed by
GC/MS gascromatography-mass spectrometry (GC/MS).
GC-M analysis was performed using an Agilent 6850A
gas chromatograph coupled to a 5973N quadrupole mass
selective detector (Agilent Technologies, Palo Alto, CA,
USA). Chromatographic separations were carried out
with an Agilent HP5ms fused-silica capillary column
(30 m × 0.25 mm i.d.) coated with 5%- phenyl-95%-
dimethylpolysiloxane (film thickness 0.25 m) as station-
ary phase as follows: injection mode: splitless at a tempera-
ture of 280◦C; column temperature program: 80◦C (2 min)
ramped to 140◦C at a rate of 10◦C/min, to 240◦C at a rate of
4◦C/min, to 280◦Cat a rate of 10◦C/min and held for 5min.
The carrier gas was helium at a constant flow of 1.0 ml/min.
The spectra were obtained in the electron impactmode at 70
eV ionization energy; ion source 280◦C; ion source vacuum
10−5 Torr.
MS analysis was performed simultaneously in TIC (mass
range scan from 50 to 600 m/z at a rate of 0.42 scans/s)
and SIM mode. GC-SIM-MS analysis was performed se-
lecting the following ions: 102 m/z for glycine, 114 m/z for
serine and 227m/z for 2-(4-chlorophenyl)ethylamine (inter-
nal standard).
Protein–RNA interaction predictions
We retrieved all the 5′UTR sequences available from the
Ensembl database (27) version GRCh38.p12. We restricted
our analysis to 164 sequences having the same length as the
SHMT2 5′UTR (UTR2) sequence and used Global Score
(28) and omiXcore (29) to predict their binding potential
and their binding affinity (Supplementary Table S2).Global
Score distinguishes interacting from non-interacting RNA-
protein pairs, while omiXcore predicts the strength in the
range [0,1] where values equal to zero suggest no interaction
and values greater than zero represent the actual predicted
binding affinity.
Statistical analysis
Data are the mean± standard deviation of at least three
independent biological experiments, each repeated in three
technical replicates. Paired samples of real time PCR data
were analysed with Student’s t-test; all the others statistical
analysis were performed using one way ANOVA followed
by the Bonferroni post-hoc comparison test. A P < 0.05
was considered significant.
RESULTS
SHMT1 binds to the 5′UTR sequences of SHMT2 and
SHMT2
SHMT1 and SHMT2 expression levels are cross-related in
lung cancer cells (11,13); however, themechanisms bywhich
their expression is controlled to ensure the appropriate
amounts of each isoform are unknown. We hypothesized
that the control may involve the interaction of SHMT1with
the 5′UTR region of the SHMT2 transcripts, since it has
been shown that SHMT1 can bind its own RNA at the
level of 5′UTR. Analysis of the expression of SHMT tran-
scripts in samples of lung adenocarcinoma (LUAD) cell
lines, obtained from the TCGA database (18), allowed us
to identify several transcripts arising from the shmt2 gene,
together with those from the shmt1 gene (Supplementary
Table S3). To assess the capability of the SHMT1 protein to
bind the 5′UTR of these transcripts in vitro, three SHMT2
RNAs, found to be expressed at different levels (more
than 90%, i.e. NM 005412; below 5%, i.e. NM 001166358,
and below 0.1% i.e. NM 001166359), and two SHMT1
transcripts sharing the same 5′UTR (i.e. NM 004169 and
NM 148918) were chosen. The features of the 5′UTR frag-
ments employed in the SHMT1-binding experiments, re-
spectively namedUTR2,UTR2int, UTR2sh andUTR1,
are shown in Figure 1 (complete nucleotide sequences re-
ported in Supplementary Table S4) together with the pre-
mRNA structure of the corresponding transcripts. To as-
sess whether SHMT1 binds to the selected RNA species,
we performed EMSA. Results showed that migration of
the UTR2 (Figure 2A and Supplementary Figure S1D),
UTR2int and UTR2sh RNA fragments (Supplementary
Figure S1A,B) was retarded in the presence of increasing
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Figure 1. Schematic representation of the pre-mRNAs of different SHMT1 and SHMT2 transcripts. Non-coding exons are colored in light blue, coding
exons in dark blue and introns are represented as thin light blue lines. The 5′UTR sequences selected for the experiments, composed by the indicated exons,
are shown in the inset. UTR1 = (NM 004169-NM148918: Ex1 21–192+Ex2 1–19). UTR2 = (NM005412:Ex1 1–205). UTR2sh = (NM 001166359:
Ex1 1–93+Ex2 1–30). UTR2 int = (NM 001166358: Ex1 1–200+Ex2 1–30).
concentrations of SHMT1 (0.3–9.6 M), indicating the for-
mation of RNA–protein complexes. SHMT1 was unable
to alter the migration of its own 5′UTR fragment (UTR1)
suggesting that the enzyme does not bind to this sequence
under the same experimental conditions and concentration
range (Figure 2B and Supplementary Figure S1C); indeed,
previous data indicate that SHMT1 can bind UTR1 (15),
but only at a very high SHMT1:RNAmolar ratio (25000:1),
which is far higher than the more stringent conditions used
in the present study.
To assess which 5′UTR sequence binds with higher rela-
tive propensity, a competition assay was performed (Figure
2C). Biotinylated UTR2 was incubated with SHMT1 in the
presence of two different concentrations of each unlabelled
UTR sequence. The fragments that displaced the bound
UTR2 RNA are UTR2 itself and UTR2int, whereas, as
expected from the experiments shown above, UTR1 did not
compete in the concentration range used. Interestingly, the
UTR2sh, which binds to the protein when assayed alone
(Supplementary Figure S1B), did not significantly compete
with the UTR2–protein complex.
An initial computational analysis, based on the Global
Score algorithm (28), predicted both UTR2 and UTR2int
as interactors (both have the maximum score of 1, while
the control RNA has a score of 0). Using omiXcore to bet-
ter evaluate the binding strength (29), only UTR2 scored
above the significance threshold (UTR2: 0.27; threshold:
0.25; UTR2int: 0.24; control: 0.14). Moreover, when com-
bining Global Score and omiXcore analysis of SHMT1 in-
teractions with a population of human 5′UTRs of the same
length (164 cases) as UTR2 (206 nt; Figure 3 and ‘Materials
and Methods’ section), UTR2 ranked in the top 2% of all
cases, indicating a strong preference for binding.
We next investigated whether the presence of the SHMT1
protein is able to modulate the levels of the SHMT2 tran-
scripts in the cells. This analysis was focused on UTR2,
which (i) is present in the most expressed transcript in lung
cancer cells (Supplementary Table S3), (ii) shows optimal
binding to SHMT1 in vitro and (iii) has an optimal interac-
tion score, as predicted by computationalmeans. The exper-
iments were carried out in the LUADH1299 cell line, a cel-
lular model in which we previously observed the cross-talk
between SHMT1 and SHMT2 (13). We transfected the cells
with an RNA interference (RNAi) against shmt1 (ishmt1)
or a scramble RNA sequence (iscr) and then studied the ex-
pression of the UTR2 by qRT-PCR. As shown in Figure
4A, SHMT1 knockdown resulted in a significant increase
of UTR2 levels. To verify if SHMT1 is able to affect the
translation of UTR2-containing transcripts in the same cell
line, a construct containing UTR2 cloned upstream of the
firefly luciferase reporter gene in the pGL3 plasmid was em-
ployed. A significant increase (5-fold) in the luciferase sig-
nal was observed only in those cells co-transfected with the
UTR2-containing plasmid and ishmt1 (Figure 4B). These
experiments demonstrate that the presence of SHMT1 re-
duces the luciferase expression in the cells when the latter
is controlled by UTR2, suggesting that SHMT1 is able to
control translation of UTR2-containing transcripts. In line
with this hypothesis, SHMT1 affects the in vitro translation
of theUTR2-luciferasemRNA (Supplementary Figure S2).
SHMT substrates modulate RNA binding
To assess if the binding of SHMT substrates (or ana-
logues) interferes with the binding of RNA, EMSA as-
says were performed in the presence of such metabolites.
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Figure 2. Electrophoretic mobility shift assay. The first two panels show
the migration of 0.08 M biotin-labelled UTR2 (A) and UTR1 (B) alone
or in the presence of the indicated concentrations of SHMT1 (3.75–125
fold excess SHMT1:RNA). (C) Competition assay performed by incu-
bating 0.08 M of biotin-labelled UTR2 with 4.8 M SHMT1 and, re-
spectively, 0.6 and 1.2 M of unlabelled competitors (UTR2, UTR2sh,
UTR2int and UTR1).
Figure 3. Global Score and omiXcore scores were linearly combined in the
Combined Interaction Score to estimate the binding preference of SHMT1
to UTR2. The cumulative distribution function of the Combined Interac-
tion Score of SHMT1 against 164 5′UTRs sequences with length of 206
nts is shown. The interaction affinity of SHMT1 against UTR2 is marked
in red (top 2% of all cases).
SHMT1 was incubated with its amino acid and/or fo-
late substrates prior to the addition of UTR2. As shown
in Figure 5A, pentaglutamylated 5-formyl-tetrahydrofolate
(5-CHO-THF-Glu5) competed with the formation of the
RNA–protein complex. The presence of a saturating con-
centration of glycine in the reaction mixture significantly
lowers the minimal folate concentration needed to compete
with UTR2 (Figure 5B). This can readily be interpreted, as
it is well known that the folate moiety has higher affinity
for the enzyme–glycine complex than for the free enzyme
(23). Interestingly, even at the highest folate concentration,
the RNA moiety was not fully displaced. Crystallographic
and solution studies on the rabbit SHMT1 (30,31) show
that the polyglutamylated folate binding stoichiometry is
0.5 per subunit (2 per tetramer). Assuming that the RNA
randomly binds to each monomer and considering that the
folate-mediated displacement affects only two subunits, it is
likely that at least 50% ofUTR2 remains bound to the other
sites, thus explaining our observations.
To further confirm the important role of glycine in the
competition between folate and RNA, we varied the glycine
concentration from 0.1 to 10 mM at fixed concentration of
5-CHO-THF-Glu5. As expected, the folate-mediated dis-
placement of the RNA from its binding site depended on
the glycine concentration, and reached a plateau at a con-
centration≥0.5 mM (Figure 5C). Notably, in the absence of
5-CHO-THF-Glu5, saturating concentrations of glycine (or
serine) did not interfere with the formation of the enzyme–
RNA complex (Supplementary Figure S3A). These exper-
iments were also performed using monoglutamylated 5-
formyl-tetrahydrofolate (5-CHO-THF-Glu1). Interestingly,
we did not observe any competition between this folate
species and the RNA for binding to SHMT1 (Supplemen-
tary Figure S3B). Moreover, in this case the presence of sat-
urating concentration of glycine only slightly affects the for-
mation of SHMT1–UTR2 complex (Supplementary Fig-
ure S3C). These results suggest that the poly-glutamate
tail is mainly responsible for the displacement of the RNA
molecule, leading us to hypothesize that the UTR2 and 5-
CHO-THF-Glu5 binding sites could partially overlap.
It is known that formation of a protein–nucleic acids
complex is often mediated not only by positively charged
side chains but also by aromatic residues making stack-
ing interactions with the nucleobases (32). In the struc-
ture of SHMT1, the folate-binding site is flanked by a
loop harbouring two lysine residues (K157 and K158), one
of which makes a salt bridge with the glutamic end of
the folate. In addition, a tyrosine residue belonging to the
other subunit (Y82′) forms an aromatic stacking interac-
tion with the aminobenzoic moiety of folate (Figure 6A and
B). To investigate whether these residues may play a role
in UTR2–RNA binding, we characterized the behaviour
of the K157S/K158S double and Y82A single mutants of
SHMT1. As shown in Figure 6 (panels C–E), the lysine mu-
tations almost completely abolished the binding of SHMT1
to UTR2, whereas, the Y82 substitution had a milder effect
(2-fold) on the formation of the SHMT1–UTR2 complex.
This further suggests that the folate and RNA-binding sites
partially superimpose and are likely located in the positively
charged region surrounding the folate binding cleft (Figure
6F).
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Figure 4. (A) Effect of SHMT1 on UTR2 levels in H1299 lung cancer cells. Expression of shmt1 and UTR2 RNAs, measured 48 h after transfection with
the iscramble (iscr) or ishmt1 (is1). (B) Effect of SHMT1 on the translation of UTR2-containing luciferase reporter mRNA in H1299 lung cancer cells. The
panel shows the ratio between firefly and Renilla luciferase evaluated 24 h after transfection with the indicated plasmids (empty pGL3 or pGL3 containing
UTR2) and the indicated RNAis. Reduction of SHMT1 by interference increases the amount of translation from UTR2-containing transcripts (UTR2
is1) with respect to control (UTR2 iscr). Statistical analysis is performed on three independent experiments. * P ≤ 0.05 ** P ≤ 0.01
Figure 5. Effect of SHMT substrates on the binding of UTR2. EMSA car-
ried out by incubating 5.4 M of SHMT1 with the indicated amounts
of 5-CHO-THF-Glu5 in absence (A) or presence (B) of 10 mM glycine
prior to the addition of 0.18 M unlabelled UTR2. (C) Effects of glycine
concentration on the folate-mediated displacement of UTR2. EMSA was
performed incubating 5.4 M of SHMT1 with the indicated amounts of
glycine and a fixed concentration of 5-CHO-THF-Glu5 (27 M) prior to
the addition of 0.18 M unlabelled UTR2.
UTR2 binding affects the enzymatic activity of SHMT1
To evaluate whether the binding of the RNA moieties af-
fects SHMT1 enzyme activity, we performed in vitro bio-
chemical assays using the selected SHMT UTR sequences;
yeast tRNA was used as a control of a RNA moiety unre-
lated to 5′UTRs. The serine hydroxymethyltransferase ac-
tivity of the enzyme, whereby L-serine and THF are con-
verted into glycine and 5,10-CH2-THF,wasmeasured by in-
cubating SHMT1 (0.2 M) with a saturating concentration
of serine (10 mM), 80 MTHF and varying concentrations
of different RNAs. The ability of SHMT1 to catalyze this
reaction was clearly inhibited by all the RNAs, although to
different degrees (Figure 7 and Supplementary Figure S5).
UTR2 showed the highest inhibitory efficacy (Figure 7A),
whereas UTR1, UTR2sh and tRNA had the lowest and
UTR2int had an intermediate inhibitory efficacy (Supple-
mentary Figure S5). The estimated apparent inhibition con-
stants (i.e. the RNA concentration required to obtain 50%
activity inhibition, IC50) are summarized in Figure 7C.
Given that UTR2 shows the higher inhibitory efficacy,
we then subdivided this fragment in shorter segments, to
better identify which region of the UTR2 is mainly respon-
sible for binding and inhibition of SHMT1. Three shorter
UTR2 segments were produced and assayed: UTR21–100,
which comprises the first 100 nts, UTR2101–206, containing
only the last 106 nts and a third segment lacking the first
50 nts (UTR251–206 ). As shown in Figure 7B and C, the
UTR21–100 segment has a 4-fold higher inhibitory capac-
ity as compared to the UTR2101–206 one, suggesting that
the region of interest is likely located in the first half of
UTR2. Interestingly, the third segment lacking only the first
50 nts (UTR251–206 in Figure 7B) behaves in a similar way
as the UTR2101–206 fragment. EMSA experiments confirm
this trend (Supplementary Figure S6).
Altogether, these findings indicate that SHMT1 likely
binds with high affinity to a sequence and/or a secondary
structure motif contained in the first 50 nts of UTR2. Since,
among all the assayed RNAs, the complete UTR2 still dis-
plays the highest binding and inhibition propensity, a syn-
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Figure 6. SHMT1 amino acid residues involved in folate and RNA binding. (A) Surface representation of the folate-binding site of human SHMT1
(hSHMT, PDB id: 1BJ4 (53)) coloured by electrostatic potential (red are acidic and blue basic residues). The substrate (5-CHO-THF-Glu1) from mouse
SHMT1 (mmSHMT1, PDB id: 1EJI (54)) is shown as sticks and superposed to the human enzyme. The location of K157, K158 and Y82′ is highlighted
by the yellow contours. (B) Superposition of the human and mouse crystal structures (in orange and grey, respectively) showing the interaction of K158
and Y82′ with the folate substrate. (C–E) EMSA assays carried out by incubating 0.24 M of unlabelled UTR2 with the indicated concentrations of
SHMT1 wild-type (WT) (C), K157S-K158S (D) and Y82A (E) mutants. The apparent dissociation constants (Kdapp) of the protein–UTR2 complexes
were measured for the WT and for the Y82A mutant, and are respectively 1.39 ± 0.30 M and 3.0 ± 0.68 M. The Kdapp value for the K157S-K158S
SHMT1 mutant cannot be calculated given the low affinity of this protein for the UTR2 RNA in the concentration range explored. (F) Surface charge
distribution of the human SHMT1 tetramer (PDB id: 1BJ4 (53)). In the blow up, 5-CHO-THF-Glu3, as observed in complex with rabbit SHMT1 (PDB
id: 1LS3 (31)), is shown as yellow spheres superposed to the human enzyme. In the rabbit structure, the 5-CHO-THF-Glu3 is bound to two subunits
(0.5 stoichiometry), with the poly-glutamylated tail making extensive and non-specific electrostatic interactions with the positively charged residues that
surround the folate binding cleft.
ergistic contribution of the complete sequence is probably
required for optimal SHMT1 binding.
The inhibitory effect of RNA on the reverse SHMT reac-
tion was measured employing two parallel experimental ap-
proaches, i.e. following the conversion of glycine and 5,10-
CH2-THF into L-serine and THF and measuring the for-
mation of the quinonoid intermediate that develops when
glycine and 5-CHO-THF-Glu bind to the enzyme forming
a ternary complex (23). Surprisingly, a milder inhibitory ef-
fect of UTR2 was observed with both kinetic assays, even
at the maximal RNA concentration employed (Supplemen-
tary Figure S7). In these experiments, UTR2 was the most
efficient inhibitor with an IC50 of ≈4 M. The formation
of the quinonoid intermediate in the presence of UTRs
was evaluated using both themono- and pentaglutamylated
form of the folate substrate but no significant differences
were observed (data not shown).
In agreement with the results obtained by EMSA analy-
ses, the activity of theK157S/K158Smutant was unaffected
by UTR2, the most efficient inhibitor of the wild-type pro-
tein (Supplementary Figure S8).
Mechanism of SHMT inhibition by RNA
To characterize the molecular mechanism of the RNA-
mediated inhibition, we performed a detailed study of
SHMT1 inhibition kinetics. Since tRNA inhibits the en-
zyme’s activity (Figure 7A), although less efficiently, and is
easily available in the large amounts necessary to perform
these experiments, we employed tRNA instead of UTR2
for the mechanistic studies. As a first step, the initial ve-
locity of the reaction was measured at different tRNA con-
centrations, keeping L-serine concentration fixed (10 mM)
and varying the THF concentration. Results show a typ-
ical THF substrate inhibition (33) (Figure 8A), which be-
came less evident at increasing tRNA concentrations. Fit-
ting of data to Equation (3) (see ‘Materials and Methods’
section), a modified Michaelis–Menten equation that ac-
counts for substrate inhibition, showed that while tRNA
increased the Km for THF, it did not affect Vmax. After
exclusion of the substrate inhibition portion of data, a
double reciprocal plot confirmed this observation, which
is typical of competitive inhibition (Figure 8B). However,
slopes (Km/Vmax) obtained by fitting the data in the dou-
ble reciprocal plot did not show the characteristic linear
dependency on inhibitor concentration, and instead exhib-
ited a hyperbolic behaviour (Figure 8C). Moreover, plots
of initial velocity measured at a fixed THF concentra-
tion as a function of tRNA clearly showed that the limit-
ing velocity as the inhibitor concentration tends to infin-
ity was not zero (Figure 7A). All these characteristics indi-
cate that tRNA is not a pure competitive inhibitor and sug-
gest a ‘partial competitive’ or ‘hyperbolic’ inhibition (34).
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Figure 7. Inactivation of SHMT1 by RNA followed by measuring the initial velocity of the hydroxymethyltransferase reaction using L-serine and THF
as substrates. (A) Inactivation of SHMT1 by three different RNAs, UTR1 (in red), UTR2 (in blue) and tRNA (in black) is reported. (B) Inactivation of
SHMT1 by three UTR2 segments, namely UTR21–100 (in orange), UTR2101–206 (in green) and UTR251–206 (in pink). All the experimental data, acquired
in three independent experiments, were fitted to Equation (2) (see ‘Materials and Methods’ section), obtaining the continuous lines shown in the figures;
the corresponding IC50 values are reported in (C). *The experimental curves for the UTR2sh and UTR2int are reported in Supplementary Figure S5.
In this particular type of inhibition, the substrate and the
inhibitor bind to partially overlapping or totally different
sites and have higher affinity for the free enzyme than for
the enzyme-inhibitor and enzyme–substrate complexes, re-
spectively. When the enzyme forms a complex with one lig-
and, the affinity for the other ligand is decreased by an equal
α factor (Figure 8G). Nevertheless, the enzyme-substrate
and the enzyme–substrate–inhibitor complexes yielded the
product with equal rate constants. Global fitting of velocity
data to Equation (4) (see ‘Materials andMethods’ section),
which combines hyperbolic competitive inhibition to sub-
strate inhibition, gave estimates of Ki for tRNA (0.031 ±
0.005 M) and of α factor (18.8 ± 4.6). It is noteworthy
that, at the highest THF concentrations used in the experi-
ments, tRNA attenuated THF substrate inhibition (Figure
8A). This paradoxical situation is caused by the decrease of
affinity for the folate substrate induced by tRNA.
In a second set of experiments, the initial velocity in the
presence of increasing tRNA was measured at a fixed THF
concentration (0.08 mM), while varying L-serine (Figure
8D). In this case, the double reciprocal plot of data (Figure
8E) and the behaviour of the obtained slopes and intercepts
(Figure 8F) indicated a pure mixed inhibition, showing that
tRNA mainly competes with folate but not with L-serine.
UTR2 modulates cellular SHMT1 activity and cell viability
To test the effect of UTR2 on SHMT1 activity in the cells,
we first used the H1299 lung cancer cell line (13). The
SHMT activity was measured in intact cells using a tech-
nique optimized by our group (25). In order to better eval-
uate the SHMT1 contribution to this activity, we have co-
transfected the H1299 cells with ishmt2, thereby silencing
SHMT2 protein expression, and with plasmids contain-
ing either UTR1, UTR2 or a control plasmid (Figure 9A).
Under these conditions, the SHMT1 activity was ∼25%
lower in the cells overexpressingUTR2with respect to those
transfected with the plasmid containing UTR1 or the con-
trol plasmid. In parallel, we also evaluated cell viability
(Figure 9B). The cells were co-transfected with ishmt2 to-
gether with UTR2 (or UTR1) expressing plasmid or pGL3
and maintained in MEM supplemented with serine. In this
cellular model, UTR2 overexpression decreased cell via-
bility by 35%; this nicely parallels the observed decrease
in SHMT activity, suggesting that the two parameters are
likely correlated.
We evaluated SHMT1 activity also in HAP1 cells, a hu-
man haploid cell line previously used as a valid metabolic
model for 1C-metabolism (21,35,36), by measuring the con-
sumption of exogenous serine. We recently reported that
SHMT2 knockout (HAP1-SHMT2KO) cells can survive
and proliferate in MEM supplemented with serine, sug-
gesting that SHMT1 in the HAP1-SHMT2KO cells is able
to perform the serine to glycine reaction, thereby comple-
menting the SHMT2 deficiency (21). Of note, the HAP1-
SHMT2KO cells were produced by a CRISPR/CAS9-
mediated frameshift of shmt2 mRNA in exon 2, and thus
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Figure 8. Mechanism of inhibition of SHMT1 catalysis by RNA. (A) Initial velocity of the SHMT reaction was measured at different THF concentrations,
in the presence of saturating L-serine (10 mM) and fixed concentrations of tRNA: 0, 0.11, 0.22, 0.44, 0.88 and 1.77 M. The continuous lines through
the experimental points (which are the average of three independent experiments) are those obtained upon the least square fitting of data to Equation
(3) (see ‘Materials and Methods’ section). (B) Double reciprocal plots of experimental points from A, after exclusion of the substrate inhibition portion
of data. The continuous straight lines through the experimental points were obtained from the independent linear fitting of data. (C) Dependence of the
slope, calculated in double reciprocal plot (B), on tRNA concentration. The continuous line through the experimental points was obtained from fitting
to a saturation curve. (D) Initial velocity of the SHMT reaction was measured at different L-serine concentrations, in the presence of 80 M THF and
fixed concentrations of tRNA: 0, 0.11, 0.22, 0.44, 0.88 and 1.77 M. The continuous lines through the experimental points (average of three independent
experiments) are those obtained upon the least square fitting of data to Michaelis–Menten equation. (E) Double reciprocal plots of experimental points
from D. The continuous straight lines through the experimental points were obtained from the independent linear fitting of data. (F) Replots of data taken
from the double reciprocal plot (E): slope (Km/Vmax; in black) and intercept (1/Vmax; in red) versus tRNA concentration. The continuous straight lines
through the experimental points were obtained from linear fitting. (G) Equilibria describing hyperbolic competitive inhibition between SHMT1 and RNA
(data shown in panels A–C). In this particular case, a saturating amino acid substrate concentration (either L-serine or glycine) is present and therefore E
corresponds to the enzyme–amino acid complex. E•S is the ternary complex with the folate substrate (either THF or CH2THF). If RNA (R) is present, it
binds to both E and E•S forming E•R and E•R•S complexes, respectively.
the SHMT2 protein is not produced (as confirmed by ex-
periments shown in Figure S9), but the mRNA, including
the UTR2 portion, is still expressed. To eliminate the pos-
sible SHMT1 inhibition, which might arise from UTR2-
containing mRNA still present in the SHMT2KO cells,
we transfected the cells with ishmt2 (or iscr as control),
prior to analysis. At 24 h after transfection, the complete
medium was exchanged for MEM supplemented with 400
M serine. We then measured serine consumption using
gas chromatography/mass spectrometry, by evaluating the
residual concentration of serine in the conditionedmedia of
the cells 48 h after medium change. As shown in Figure 9C,
HAP1-SHMT2KO cells transfected with ishmt2 consumed
twice as much serine as the control cells (transfected with
iscr); thus, serine consumption is modulated by the presence
of UTR2-RNA, an effect which can be due to UTR2 bind-
ing to SHMT1.
In a parallel experiment, the HAP1-SHMT2KO cells
were transfected with pGL3 alone, UTR1 or UTR2-
containing vectors and serine was measured as described
above. In these experiments, according to our working hy-
pothesis, overexpression of UTR2 should affect SHMT1-
driven serine consumption. Confirming our prediction,
residual serine in themediumwas 40%higher in the cultures
transfected with UTR2 than in cells transfected with UTR1
or the control plasmid pGL3 (Figure 9D). These results
highlighted that the biological effect was UTR2-specific.
To analyse whether the UTR2-containing mRNA af-
fects cell viability, we transfected HAP1-SHMT2KO cells
with either ishmt2 or iscr, and then cultured the cells in
MEM supplemented with serine or glycine + formate and
evaluated the number of live cells. As mentioned above,
transfection with ishmt2 should eliminate the SHMT1 in-
hibition, which might arise from UTR2-containing mRNA
still present in the SHMT2KO cells. We found a ∼35% in-
crease in ishmt2-transfected cell viability over equivalent
iscr-transfected cells only when MEM was supplemented
with serine (Figure 9E). To further show that cell viability
is related to SHMT1 activity, we have supplemented MEM
with dTMP, a metabolite whose synthesis requires the CH2-
THF produced in the serine to glycine breakdown mainly
catalyzed by SHMT1 (11). Consistent with our hypothesis,
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Figure 9. SHMT activity and cell viability in H1299 and HAP1-
SHMT2KO cells. (A) SHMT enzymatic activity in H1299 cells 48 h af-
ter transfection with the indicated plasmids (pGL3 alone or with UTR1
and UTR2, respectively) and iRNAs measured by tritium-exchange ra-
dioisotopic assay. (B) Cell viability evaluated by Trypan blue exclusion as-
say in H1299 cells cultured in MEM supplemented for 24 h with 0.4 mM
serine the day after transfection with the indicated iRNAs and/or plas-
mids. SHMT1 activity in HAP1-SHMT2KO cells assessed evaluating ser-
ine residual concentration in the supernatants 72 h after transfection with
the indicated RNAis (C) or plasmids (D). (E) Cell viability evaluated in
HAP1-SHMT2KO cells cultured in MEM supplemented for 48 h with 0.4
mM glycine (G) + 0.5 mM formate (F), 0.4 mM serine (S) and/or 30 M
thymidine 5′monophosphate (dTMP) the day after transfection with the
indicated RNAis (E) or plasmids (F and G). Statistical analysis are per-
formed on three independent experiments * P ≤ 0.05.
dTMP supplementation led to similar cell viability in both
iscr- and ishmt2-transfected cells (Figure 9E).
Finally, to assess if the overexpression of UTR2 in
SHMT2-KO cells could also affect cell viability, the cells
were transfected with a pGL3 plasmid with or without
UTR2 and UTR1. Trypan blue exclusion assay demon-
strated that UTR2 overexpression induced a decrease in cell
viability of ∼40%, but only when cells were grown in MEM
supplemented with serine, an effect that was not observed
with UTR1 (Figure 9 F and G).
DISCUSSION
Cell proliferation is necessarily a tightly regulated mecha-
nism and 1C-metabolism is at the heart of the production
of precursors necessary for proliferation. SHMT proteins
are central players in 1C-metabolism in normal and can-
cer cells (37), as is evident by the recent focus on these en-
zymes in the literature (37,38). 1C-metabolism is compart-
mentalized with dedicated cytosolic (SHMT1) and mito-
chondrial (SHMT2) enzymes and the exchange of metabo-
lites was shown to link the two compartments (5). Previous
evidence has shown that SHMT1 is able to shift its activ-
ity to produce serine from glycine or vice versa, depending
on the metabolic needs of the cells, thus supporting 1C-
metabolism (5). The present study reports a novel regula-
tory mechanism that depends on the moonlighting prop-
erty of cytosolic SHMT1 to bind specific RNA molecules
and suggests that the formation of the SHMT1–RNA com-
plex has far-reaching consequences, as it is able to fine-tune
SHMT2 expression and, at the same time, to modulate the
enzymatic activity of SHMT1.
We showed that human SHMT1 is able to bind in
vitro to SHMT2 5′UTR sequences and provided evidence
to suggest that this interaction might cooperate to con-
trol cellular SHMT2 mRNA and protein levels. SHMT
isozymes have been previously suggested to be potential
RNA-binding proteins (39) and in vitro experiments indi-
cated that SHMT1 is capable of autogenously regulate its
expression by binding to the 5′UTR of its mRNA, in a
similar manner to that reported for TYMS and DHFR,
the other two enzymes of the thymidylate cycle (2,3,15).
This RNA-binding property of SHMT is evolutionary con-
served, as it was also observed in Plasmodium SHMT (40).
TheRNAs identified in the present study (SHMT2 5′UTRs)
exhibit a high affinity for the SHMT1 protein. More impor-
tantly, our observations on theUTR2RNAallow us to pro-
pose a novel regulatorymechanism connecting the cytosolic
and mitochondrial SHMT-dependent 1C-metabolism.
Metabolites, including SHMT substrates, play an impor-
tant role in the cross-talk between the cytosolic and mito-
chondrial compartments of 1C-metabolism. Here, we ad-
dressed whether and how SHMT-related metabolites might
also affect the formation of the RNA/protein complex. Dif-
ferent molecular mechanisms, such as mutually exclusive
binding to the same protein region, allosteric control or
even control of metabolite-driven post-translational mod-
ifications could explain the effect of metabolites on the
protein–RNA complex formation (1). We show here that
serine and glycine alone are not sufficient to perturb the for-
mation of the SHMT1–RNA complex in vitro, whereas the
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pentaglutamylated folate competes with UTR2 for bind-
ing to SHMT1, an effect that is enhanced by increasing
the glycine concentration. Our results thus support the idea
that glycine and folate(s) modulate the formation of the
SHMT1–RNA complex. It should be underscored here that
the amounts of 5-CHO-THF-Glu5 and glycine necessary to
compete for the in vitro binding of UTR2 fall within the
physiological range (41). Moreover, based on our results
with penta- and mono-glutamylated species in the presence
of glycine, we predict that also polyglutamylated folates, the
predominant form of folates in all organisms (42,43), can be
effective competitors of RNA binding in the cell.
The competition between folates andRNA, together with
the findings from the site-directed mutants and the kinetic
characterization showing hyperbolic inhibition behaviour,
strongly suggest that the RNA-binding site on SHMT1
involves the folate main binding cleft. However, the ob-
served difference in binding between the mono- and penta-
glutamylated folate species highlights that the polyGlu tail
is critical in determining binding propensity, suggesting
that the RNA-binding site likely extends beyond the sub-
strate binding site, involving the positively charged residues
that surround the folate binding cleft (Figure 6F). We
thus believe that this region can be considered a non-
canonical RNA-binding site. Interestingly, binding of se-
lenocysteinyl tRNA (tRNASec) by human O-phosphoseryl-
tRNA:selenocysteinyl-tRNA synthase (SepSecS), the en-
zyme that catalyzes the final step of selenocysteine synthe-
sis, also occurs through a similar interface (44). SepSecS
belongs to the same family of fold-type I pyridoxal phos-
phate enzymes that include SHMT (44–46) and has a qua-
ternary structure closely resembling that of human SHMT.
The conservation of the non-canonical RNA-binding site
across different members of this fold type may suggest that
other proteins of this family could be involved in RNA
binding, possibly regulating other cellular processes.
Interestingly, the formation of the metabolite-sensitive
RNA–protein complex also exerts an RNA-mediated con-
trol on SHMT1 enzymatic activity. The cleavage of serine is
decreased in the presence of RNA, withUTR2 appearing as
the strongest inhibitor (IC50 ∼33 nM). The notion that the
competition between an enzyme’s cofactor/substrate and
RNA can affect the catalytic activity is already known for
other metabolic enzymes, including GAPDH (47). On the
other hand, the discovery that the RNA-mediated inhibi-
tion can act selectively is unprecedented, as has not previ-
ously been observed for SHMTor othermetabolic enzymes.
Our results show for the first time that, whereas RNA bind-
ing inhibits serine cleavage, unexpectedly the reverse reac-
tion (SHMT1-driven conversion of glycine into serine) is
much less affected. Binding of RNA to the SHMT–serine
complex somehow hampers the binding of the folate sub-
strate more than binding of RNA to the SHMT–glycine
complex. A possiblemechanistic interpretation is illustrated
in the scheme shown in Figure 8G, assuming the value of
the α factor to be higher in the forward SHMT reaction
(serine to glycine direction) than in the reverse SHMT re-
action (glycine to serine direction). It is known that the
SHMT-serine and SHMT–glycine complexes are in a dif-
ferent conformational status; in particular L-serine bind-
ing induces an open-to-close conformational change that
rearranges the protein region close to the active site. This
change that does not occur upon binding of glycine (48).
Therefore, it is plausible that the interaction of RNA with
such dissimilar conformations of the enzyme may differen-
tially affect the binding of the folate substrate and the sub-
sequent catalytic steps. Accordingly, SHMT small molecule
inhibitors show a similar behaviour, mainly affecting the hy-
droxymethyltransferase reaction when serine acts as a sub-
strate (21,49). The in vitro results presented here on UTR2
segments (Figure 7B) strongly suggest that it is possible to
identify shorter constructs capable of maintaining a reason-
able affinity and inhibition potential for SHMT, a proof-
of-concept of the feasibility of designing nucleic acid-based
SHMT inhibitors.
The observedRNA-mediated inhibition of SHMT1 char-
acterized in vitro was validated using SHMT2-knockdown
and null cell lines. First, UTR2 (but not UTR1) RNA low-
ers the SHMT intracellular activity, highlighting the speci-
ficity of UTR2-mediated inhibition. Second, in a SHMT2-
null background, serine consumption increaseswhenUTR2
is removed, whereas its overexpression leads to an accumu-
lation of this amino acid in the medium, suggesting that
the serine to glycine reaction is inhibited. Finally, the in-
hibition of SHMT1 by UTR2 also correlates with a signifi-
cant reduction of cell viability in serine-containingmedium.
These data suggest that in these models, in the absence
of SHMT2, when the hydroxymethyltransferase reaction is
catalyzed by the cytosolic isozyme, a decrease of cell viabil-
ity occurs, which is likely due to reduced serine consumption
by SHMT1 following the formation of the protein–RNA
complex.
Future analysis will be needed to fully elucidate the struc-
tural features of the non-canonical RNA-binding domain
of SHMT1, as well as of its complexes withRNA, and to as-
sess the effectiveness in the cells of novel nucleic acid-based
inhibitors of the SHMTenzyme, which represents an attrac-
tive target for novel metabolic anti-tumour chemotherapy.
Our study adds a novel and thus far unpredicted layer
of complexity to the regulation of SHMT expression and
activity. SHMT was already known to be controlled at
both transcriptional (50) and post-translational level (51)
and a cross-talk between SHMT1 and SHMT2 expression
has also been reported (5,13). Nevertheless, the molecu-
lar mechanisms by which one protein could affect the ex-
pression of the other isoform were unclear. In our cel-
lular models, the RNA-binding activity of SHMT1 plays
an important role, controlling SHMT2 expression, at least
in part, at the translational level. In the working hypoth-
esis presented here, when SHMT2 mRNA is highly ex-
pressed, the cytosolic enzyme SHMT1 likely binds to it
and the glycine to serine conversion by the cytosolic en-
zyme is favoured. When SHMT2 levels are reduced, the
SHMT1 enzyme can work in the opposite direction, as
the RNA-mediated inhibition is relieved. In parallel, re-
ducing SHMT1 protein levels may affect SHMT2 mRNA
levels available for translation, thus favouring SHMT2 ex-
pression. Other metabolic parameters, such as the distribu-
tion and levels of metabolites (folate species, glycine and
indirectly possibly also NADH/NADPH) might also con-
tribute to this RNA-mediated regulatory mechanism. Alto-
gether, this strategy may contribute to maintain the direc-
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tionality of the SHMT1 reaction towards serine synthesis,
also allowing the intracellular serine to be metabolized in
the mitochondria. Although we are aware that the specific
traits of this regulation may vary in different cellular mi-
lieus, we noticed that UTR2-containing transcripts are also
highly expressed in other tissues (Tables S5-S7 for colon,
liver and kidney), thus it would be worth to investigate if the
cross-regulation mechanism presented here is active also in
these histotypes.
Finally, since downregulation of SHMT1 was found as-
sociated with the modulation of the expression of several
genes (52), we believe that our findings are just a small part
of a broader phenomenon in which SHMT1 (53,54), as fre-
quently observed for RNA-binding proteins (55), poten-
tially regulates the expression of multiple genes at the post-
transcriptional level. Future studies will attempt to charac-
terize in-depth the regulatory role of the cytosolic SHMT, to
date unexplored. Furthermore, the relevance of the RNA-
binding activity of mitochondrial SHMT will also need to
be addressed.
Overall, the metabolite-RNA competition events shown
in this work fit well within the general model by which al-
terations in cellular metabolism are sensed by metabolic
enzymes via RNA (or vice versa) as suggested in the so-
called ‘REM (RNA–enzyme–metabolite) hypothesis’ (56).
This scenario is becoming increasingly more important as
the expanding fields of metabolic studies and RNA com-
plexity controlling cell function begin to intersect.
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